Epix Medical President and COO Knight resigns

TriMed Staff | | Health Imaging | Artificial Intelligence
Epix Medical Inc. this week announced the departure of President and COO Stephen C. Knight, M.D.

 Knight will remain with Epix through the company's NDA submission for MRI contrast agent MS-325. He eventually will assume the title of president for Fidelity Biosciences Group, a unit of Fidelity Investments.

 CEO Michael D. Webb will assume title of President of the Cambridge, Mass.-based company that specializes in pharmaceuticals for MRI.

TriMed Staff

Related Content

How AI 'cheating' could impact algorithm reliability
New AI program delivers rapid, accurate echo video assessments
Do large language models help or hinder workflows related to radiology reports?
Hospital creates 'virtual reality technologist' role to support patients during interventional procedures
Radiomics model links brain MRI features with neuropsychological changes in Crohn's disease
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.